

[illegible]

KVHGSLARAGKVRGQTPKVAQEKKKKKTGRAKRRMQYNRRFVNVPVPTFGKKKKGPNANS

Ubiquitin:
(59aa, 6.654 kD)

(1-18, 2.153 kD) **KVHGSLARAGKVRGQTPK**

(29-41, 1.910 kD) TGRAKRRMQYNRR

(18-29, 1.643 kD) KVAQEQKKKKKT

(18-35, 3.477 kD) KVAQEKKKKKTGRAKRR

(18-35, 3.656 kD) AKVAQEKKKKKTGRAKRRRA

(29-35, 953 D) TGRAKRR

(42-59, 2.213 kD) FVNVPFTFGKKKGPNANS

(36-41, 957 D) MQYNRR

FIG. 1

2/17






FIG. 2A

3/17

FIG. 2B

4/17

FIG. 3

5/17




FIG. 4

6/17




FIG. 5

7/17




FIG. 6

8/17




FIG. 7

9/17

Effect of ubi (18-35) and D-ala-protected ubi (18-35) on *S. aureus* and antibiotic-resistant *S. aureus* (MRSA)




FIG. 8

10/17

Effect of D-ala-protected ubi (18-35) on *E. coli*
and antibiotic-resistant *E. coli*





FIG. 9

11/17

Infection model

FIG.10

12/17

Accumulation of ^{99m}Tc -labelled ubiquidine (18-35) in the thigh muscle infected by staphylococcus aureus ATCC 25923 after intraperitoneal injection




FIG.11

13/17

Accumulation of ^{99m}Tc -labelled peptides in the thigh muscle infected by *Klebsiella pneumoniae* ATCC 43816






FIG. 12

FIG. 13


Accumulation of 99 Tc-labelled ubiquitinidine 18-35 in an infection but not in inflammations



15/17


FIG. 14A

16/17


FIG. 14B

17/17

Antimicrobial effect of ubiquidine 29-41 and 18-35 and defensin-1
in mice



Antimicrobial effect of ubiquidine 29-41 and 18-35 and defensin-1
in mice treated with cyclophosphamide

FIG.15